Granted Patent B2

US 12,466,840 · App. 18/920,212 · Granted Nov 11, 2025

Inventors: Shuhei Kawamura (Cambridge, MA); Yu Kobayakawa (Ibaraki, JP); Tsuyoshi Oshima (Ibaraki, JP); Takao Uno (Ibaraki, JP); Patrick Schöpf (London, GB)

Assignee: Merck Sharp & Dohme LLC

C07D498/22A61K31/553A61K45/06A61P35/00C07D519/00

Abstract

Claims (32)

1 . A compound of:

or a pharmaceutically acceptable salt thereof.

2 . A compound of:

or a pharmaceutically acceptable salt thereof.

3 . A compound of:

or a pharmaceutically acceptable salt thereof.

4 . A compound of:

or a pharmaceutically acceptable salt thereof.

5 . A pharmaceutical composition comprising the compound of claim 1 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

6 . A pharmaceutical composition comprising the compound of claim 2 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

7 . A pharmaceutical composition comprising the compound of claim 3 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8 . A pharmaceutical composition comprising the compound of claim 4 or the pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

9 . A pharmaceutical composition comprising the compound of claim 1 or the pharmaceutically acceptable salt thereof, an additional anti-cancer agent, and a pharmaceutically acceptable carrier.

10 . A pharmaceutical composition comprising the compound of claim 2 or the pharmaceutically acceptable salt thereof, an additional anti-cancer agent, and a pharmaceutically acceptable carrier.

11 . A pharmaceutical composition comprising the compound of claim 3 or the pharmaceutically acceptable salt thereof, an additional anti-cancer agent, and a pharmaceutically acceptable carrier.

12 . A pharmaceutical composition comprising the compound of claim 4 or the pharmaceutically acceptable salt thereof, an additional anti-cancer agent, and a pharmaceutically acceptable carrier.

13 . A method of treating cancer comprising inhibiting at least one of KRAS-G12D protein, KRAS-G12C protein, KRAS-G12V protein, and KRAS-G13D protein by administering a therapeutically effective amount of the compound of claim 1 , or the pharmaceutically acceptable salt thereof, to a subject in need of such treatment.

14 . A method of treating cancer comprising inhibiting at least one of KRAS-G12D protein, KRAS-G12C protein, KRAS-G12V protein, and KRAS-G13D protein by administering a therapeutically effective amount of the compound of claim 2 , or the pharmaceutically acceptable salt thereof, to a subject in need of such.

15 . A method of treating cancer comprising inhibiting at least one of KRAS-G12D protein, KRAS-G12C protein, KRAS-G12V protein, and KRAS-G13D protein by administering a therapeutically effective amount of the compound of claim 3 , or the pharmaceutically acceptable salt thereof, to a subject in need of such treatment.

16 . A method of treating cancer comprising inhibiting at least one of KRAS-G12D protein, KRAS-G12C protein, KRAS-G12V protein, and KRAS-G13D protein by administering a therapeutically effective amount of the compound of claim 4 , or the pharmaceutically acceptable salt thereof, to a subject in need of such treatment.

17 . A method of treating cancer comprising administering a therapeutically effective amount of the compound of claim 1 , or the pharmaceutically acceptable salt thereof, to a subject in need of such treatment.

18 . A method of treating cancer comprising administering a therapeutically effective amount of the compound of claim 2 , or the pharmaceutically acceptable salt thereof, to a subject in need of such treatment.

19 . A method of treating cancer comprising administering a therapeutically effective amount of the compound of claim 3 , or the pharmaceutically acceptable salt thereof, to a subject in need of such treatment.

20 . A method of treating cancer comprising administering a therapeutically effective amount of the compound of claim 4 , or the pharmaceutically acceptable salt thereof, to a subject in need of such treatment.

21 . The method of claim 17 , further comprising administering an additional active agent to the subject.

22 . The method of claim 18 , further comprising administering an additional active agent to the subject.

23 . The method of claim 19 , further comprising administering an additional active agent to the subject.

24 . The method of claim 20 , further comprising administering an additional active agent to the subject.

25 . The compound of claim 1 , wherein the compound is:

26 . The compound of claim 2 , wherein the compound is:

27 . The compound of claim 3 , wherein the compound is:

28 . The compound of claim 4 , wherein the compound is:

Assignments (7)

Continuity (4)

References Cited (346)